Dosing on the agenda

Decision on PPI double dosing deferred by PBAC, but support given to antibiotic listing changes The Pharmaceutical Benefits Advisory Committee (PBAC) has deferred a decision on whether to allow twice daily dosing of PPIs for approved patients. PBAC had been asked to consider changes following feedback received by the Department of Health concerning the PBS